CASE STUDY (US)
Client’s specialty product had a complicated oral therapy regimen requiring supplemental support to patients. Therapy administered for chronic life-threatening condition in which patients are generally older and polypharmic.
We built a team of Clinical Educators with strong therapeutic backgrounds to engage and stratify patients into high, medium, and low risk adherence categories based on their own answers in a non-adherence risk assessment typing tool.
Provided insight-driven ongoing patient and caregiver support through multichannel communication cadence based on non-adherence risk segment.
Closed the loop with the healthcare professional on feedback from patients and Clinical Educators.
Patients in the program receiving personalized Clinical Educator support on average stayed on the product for 2.5 more cycles (2.5 months) than patients not enrolled in the adherence support program.
The probability of patients in the program to refill their next prescription was 92% versus 63% probability for those not enrolled in the adherence support program.
|
Enrolled Patients |
Non-Enrolled Patients |
|
|
|
92% |
63% |
2.5 |
Our client was new to the complement system space and was preparing to launch an oral, first-in-class medication in a rare blood disease.
Read moreA top 10 pharma company wanted dermatologists to own the conversation on PsA, and become confident in diagnosing the disease.
Read moreA top 10 global pharma company wanted to challenge the status quo when it came to planning and prioritizing congresses.
Read more